GW Pharmaceuticals PLC (NASDAQ:GWPH) has earned a consensus rating of “Buy” from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $151.83.

Several analysts recently weighed in on GWPH shares. Maxim Group set a $135.00 price target on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday, August 7th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $208.00 price target on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, August 8th. ValuEngine upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st.

Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) traded up 1.02% during midday trading on Friday, reaching $108.23. 239,954 shares of the company were exchanged. GW Pharmaceuticals PLC has a 52 week low of $92.65 and a 52 week high of $137.88. The firm has a 50-day moving average of $105.92 and a 200 day moving average of $110.11. The firm’s market capitalization is $2.74 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.34). The business had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same period in the prior year, the company posted ($0.05) EPS. On average, equities research analysts expect that GW Pharmaceuticals PLC will post ($5.94) EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. lifted its holdings in GW Pharmaceuticals PLC by 4.6% in the first quarter. Alliancebernstein L.P. now owns 286,475 shares of the biopharmaceutical company’s stock valued at $34,646,000 after acquiring an additional 12,519 shares during the period. Blair William & Co. IL acquired a new stake in GW Pharmaceuticals PLC in the first quarter valued at $207,000. Victory Capital Management Inc. lifted its holdings in GW Pharmaceuticals PLC by 9.2% in the second quarter. Victory Capital Management Inc. now owns 308,945 shares of the biopharmaceutical company’s stock valued at $30,971,000 after acquiring an additional 25,920 shares during the period. Eqis Capital Management Inc. lifted its holdings in GW Pharmaceuticals PLC by 23.3% in the second quarter. Eqis Capital Management Inc. now owns 2,899 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 547 shares during the period. Finally, HighTower Advisors LLC lifted its holdings in GW Pharmaceuticals PLC by 10.3% in the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 191 shares during the period. 75.07% of the stock is owned by institutional investors.

WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/16/gw-pharmaceuticals-plc-gwph-given-average-recommendation-of-buy-by-brokerages.html.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.